Department of Pharmacy, Children's Hospital Colorado.
Department of Pediatrics, Section of Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO.
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e293-e295. doi: 10.1097/MPH.0000000000002014.
Relapse of infection due to SARS-CoV-2 has been rarely described and there is little guidance regarding the management of such cases in immunocompromised hosts. We present a case of an adolescent female with B-cell acute lymphoblastic leukemia hospitalized multiple times for symptomatic SARS-CoV-2 infection who was safely treated with 2 courses of remdesivir (RDV) and has had no additional readmissions to date. Though additional studies are needed to confirm the safety and efficacy of an additional course of RDV in the setting of relapsed or prolonged severe COVID-19, our observations suggest that a second course of RDV may be considered.
由 SARS-CoV-2 引起的感染复发很少被描述，对于免疫功能低下宿主的此类病例的处理也几乎没有指导。我们报告了一例患有 B 细胞急性淋巴细胞白血病的青少年女性，她因有症状的 SARS-CoV-2 感染多次住院，使用 2 个疗程的瑞德西韦（RDV）安全治疗，迄今为止没有再次入院。尽管需要进一步的研究来确认在复发或持续严重 COVID-19 情况下额外疗程的 RDV 的安全性和有效性，但我们的观察结果表明可以考虑第二个疗程的 RDV。
